Skip to content

A Ray of Light in Muddy Waters? The CJEU Rules on Combination SPCs in C-121/17 Teva v Gilead

Timo Minssen, Sven J.R. Bostyn

DOI https://doi.org/10.21552/eplr/2018/3/9



Timo Minssen is a Professor of Law, Founding Director, Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) at the University of Copenhagen, Denmark. For correspondence: <mailto:timo.minssen@jur.ku.dk>. Sven Bostyn is an Associate Professor of Biomedical Innovation Law, CeBIL, University of Copenhagen, Denmark. For correspondence: <mailto:sven.bostyn@jur.ku.dk> Acknowledgments & Disclaimer:CeBIL’s research is supported by a Novo Nordisk Foundation grant for a scientifically independent Collaborative Research Program (grant agreement number NNF17SA027784). Timo Minssen was also a member of the Expert Board for Copenhagen Economics’ ‘Study on the economic impact of SPCs, Pharmaceutical incentives and rewards in Europe’ (European Commission (DG GROW) - Tender reference number 590/PP/GRO/SME/16/F/121). Sven Bostyn was an expert co-author of the Technopolis Study commissioned by the Dutch Ministries of Health and Economic Affairs and Climate: S.J.R Bostyn, et al, ‘Effects of Supplementary Protection Mechanisms for Pharmaceutical Products’ (May 2018) Technopolis Group, 169.

Share


Lx-Number Search

A
|
(e.g. A | 000123 | 01)

Export Citation